


We claim:

1. A compound of formula (I),



wherein:

- 5 R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, alkoxy C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-OR_c$, $-NO_2$, and $-N(R_c)_2$;
 each R_c is independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;
- 10 R_7 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl, all of which are optionally substituted by one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;
- 15 R_8 and R_9 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one or more substituents independently selected from halogen, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl; and
- 20 pharmaceutically acceptable salts and solvates thereof.
2. A compound according to claim 1, wherein: R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from hydrogen, $-N(R_c)_2$, and $-NO_2$.
- 25 3. A compound according to claim 1, wherein R_7 is C_1 - C_6 alkyl, optionally substituted with aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, wherein said aryl, cycloalkyl, heterocycloalkyl, and heteroaryl are optionally substituted with at least one substituent selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl.
- 30 4. A compound according to claim 1, wherein R_8 and R_9 are independently selected from hydrogen and C_1 - C_6 alkyl, wherein said alkyl group is optionally substituted with aryl, and

wherein said aryl is optionally substituted with at least one substituent selected from halogen and C₁-C₆ alkyl.

5. A compound according to claim 1, wherein:
5 R₁, R₂, R₃, R₄, R₅, R₆ are independently selected from hydrogen, -NH₂; and -NO₂;
R₇ is 4-fluorobenzyl, (5-chlorothiophen-2-yl)methyl, 3-chloro-2-fluorobenzyl, benzyl, 4-methylbenzyl, 2,4-difluorobenzyl, 3-chloro-2,6-difluorobenzyl, or 3-chlorobenzyl; and
R₈ and R₉ are independently selected from hydrogen, methyl, and benzyl.
- 10 6. A compound according to claim 1, wherein:
R₁, R₂, R₃, R₄, R₅ and R₆ are hydrogen;
R₇ is -CH₂phenyl, wherein said phenyl is substituted with at least one substituent
chosen from fluorine and chlorine;
R₈ is hydrogen or -CH₃; and
15 R₉ is hydrogen or -CH₃.
7. A compound according to claim 1, wherein:
R₁, R₂, R₃, R₅ and R₆ are hydrogen;
R₄ is -NO₂ or -NH₂;
20 R₇ is -CH₂phenyl, wherein said phenyl is substituted with at least one substituent
chosen from fluorine and chlorine;
R₈ is hydrogen or -CH₃; and
R₉ is hydrogen or -CH₃.
- 25 8. A compound according to claim 1, wherein:
R₁, R₂, R₃, R₄, R₅ and R₆ are hydrogen;
R₇ is -CH₂phenyl, wherein said phenyl is substituted with at least one substituent
chosen from fluorine and chlorine; and
R₈ and R₉ are hydrogen.
- 30 9. A compound according to claim 1, wherein:
R₁, R₂, R₃, R₄, R₅ and R₆ are hydrogen;
R₇ is -CH₂phenyl, wherein said phenyl is substituted with at least one substituent
chosen from fluorine and chlorine; and
35 R₈ and R₉ are -CH₃.
10. A compound according to claim 1, wherein:

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrogen;

R_7 is $-\text{CH}_2\text{phenyl}$, wherein said phenyl is substituted with at least one substituent chosen from fluorine and chlorine;

R_8 is hydrogen; and

5 R_9 is $-\text{CH}_3$.

11. A compound according to claim 1, wherein:

R_1, R_2, R_3, R_4, R_5 and R_6 are hydrogen;

10 R_7 is $-\text{CH}_2\text{phenyl}$, wherein said phenyl is substituted with at least one substituent chosen from fluorine and chlorine;


R_8 is $-\text{CH}_3$; and

R_9 is hydrogen.

12. A compound according to claim 1, selected from 9-(4-fluorobenzyl)-*N*-hydroxy-9*H*- β -

15 carboline-3-carboxamide; 9-[(5-chlorothien-2-yl)methyl]-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-(3-chloro-2-fluorobenzyl)-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-Benzyl-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-(4-methylbenzyl)-*N*-Hydroxy-9*H*- β -carboline-3-carboxamide; 9-(2,4-difluorobenzyl)-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-(3-chloro-2,6-difluorobenzyl)-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 6-amino-9-(3-chlorobenzyl)-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-(3-chloro-2,6-difluorobenzyl)-*N*-methoxy-9*H*- β -carboline-3-carboxamide; *N*-(benzyloxy)-9-(3-chloro-2,6-difluorobenzyl)-9*H*- β -carboline-3-carboxamide; 9-(3-chloro-2,6-difluorobenzyl)-*N*-hydroxy-*N*-methyl-9*H*- β -carboline-3-carboxamide; *N*-benzyl-9-(3-chloro-2,6-difluorobenzyl)-*N*-hydroxy-9*H*- β -carboline-3-carboxamide; 9-(4-fluorobenzyl)-*N*-hydroxy-*N*-methyl-9*H*- β -carboline-3-carboxamide; and
25 pharmaceutically acceptable salts and solvates thereof.

13. A compound of formula (Ib),



30

wherein:

R_1 , R_3 , R_4 , R_5 , and R_6 are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, alkoxy C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-OR_c$, $-NO_2$, and $-N(R_c)_2$;

each R_c is independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;

5 R_7 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl, all of which are optionally substituted by one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;

10 R_9 is independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one or more substituents independently selected from halogen, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;

15 each R_{10} and R_{11} are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl, $-OR_c$, or $-N(R_c)_2$ group, wherein said alkyl, alkenyl, and alkynyl are optionally substituted by one or more substituents selected from halogen, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group, wherein said aryl, cycloalkyl, heterocycloalkyl, and heteroaryl are optionally substituted with at least one substituent independently selected from halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl;

n is 1, 2 or 3; and

pharmaceutically acceptable salts and solvates thereof.

25 14. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound according to claim 1 and a pharmaceutically acceptable carrier, diluent, or vehicle.

30 15. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound according to claim 12 and a pharmaceutically acceptable carrier, diluent, or vehicle.

35 16. A method of inhibiting or modulating the activity of human immunodeficiency virus (HIV) integrase enzyme, comprising contacting said enzyme with an effective amount of at least one compound according to claim 1.

17. A method of inhibiting or modulating the activity of human immunodeficiency virus (HIV) integrase enzyme, comprising contacting said enzyme with an effective amount of at least one compound according to claim 12.
- 5 18. A method of treating a disease or condition mediated by human immunodeficiency virus (HIV) integrase enzyme, comprising administering to a mammal in need of such treatment a therapeutically effective amount of at least one compound according to claim 1.
- 10 19. A method of treating a disease or condition mediated by human immunodeficiency virus (HIV) integrase enzyme, comprising administering to a mammal in need of such treatment a therapeutically effective amount of at least one compound according to claim 12.
- 15 20. A method of inhibiting the replication of human immunodeficiency virus (HIV) in a mammal, comprising administering a human immunodeficiency virus-inhibiting amount of a compound according to claim 1 to said mammal.
- 20 21. A method of inhibiting the replication of human immunodeficiency virus (HIV) in a mammal, comprising administering a human immunodeficiency virus-inhibiting amount of a compound according to claim 12.
- 25 22. A method of inhibiting the activity of the HIV integrase enzyme, comprising contacting said enzyme with a HIV integrase enzyme-inhibiting amount of a compound according to claim 1.
23. A method of inhibiting the activity of the HIV integrase enzyme, comprising contacting said enzyme with a HIV integrase enzyme-inhibiting amount of a compound according to claim 12.